Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px download
Document › Details

Curasan AG. (10/1/14). "Press Release: Change of CEO as of October 7th 2014 and Capital Increase with Subscription Rights". Kleinostheim.

Organisations Organisation 4SC AG
  Group 4SC (Group)
  Organisation 2 YA Global Master SPV Ltd.
  Group Yorkville Group (Group)
Products Product private equity
  Product 2 small-molecule drug
Index terms Index term 4SC–Yorkville Group: credit, 201403 first tranche €500k convertible notes under up to €15m agreem from 2/14 w YA Global Master SPV Ltd
  Index term 2 4SC–Yorkville Group: credit, 201402– up to nominally €15m convertible notes to be purchased until 12/16 by YA Global Master SPV Ltd
Persons Person Schlenk, Michael (Curasan 201410– Executive Board Director before Centogene + ProBioGen)
  Person 2 Gabriel, Raimund (MC Services 1999–201101– Founder + CEO)
     


The Supervisory Board of curasan AG announced today that Michael Schlenk will be instated as CEO as of October 7, 2014.

Michael Schlenk, MBA, provides excellent Know-How and extensive experience in management of international pharmaceutical and biotechnology companies, which should foster the further development of curasan AG. He has held leading positions at Sandoz, Novartis, and Abbott; both within Europe and internationally. His most recent appointment was as CEO and major stockholder of Centogene Holding AG. Since July 2014 he remains on the Board of Directors of Centogene.

The current CEO of curasan AG, Hans-Dieter Rössler, will step down from his position as of October 6th. He will assist Mr. Schlenk in an advisory role as needed, at least until completion of his contract, which is foreseen to be the end of this year.

The supervisory Board have also approved the increase of the capital of the company by up to EUR 3.648.733 to up to EUR 10.946.199 using the authorized capital 2013. Existing shareholders will be offered 1 new share for every 2 existing shares. It is expected and planned that Michael Schlenk, the incoming CEO, will acquire a portion of the outstanding shares out of not allocated options and therefore become an Investor in curasan AG.

   
Record changed: 2017-08-24

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for 4SC (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px




» top

Advertisements

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 41 Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 22 Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px